Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OESIRI: Nal-IRI/5-FU vs Paclitaxel in Metastatic ESCC
NCT03719924Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fédération Francophone de Cancérologie Digestive. Started Mar 2019; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03719924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719924.